Role of Nitric Oxide Synthase in NO Production, Inflammatory Regulation, and Oxidative Stress Research
Role of Nitric Oxide Synthase in NO Production, Inflammatory Regulation, and Oxidative Stress Research
Nitric oxide synthase (NOS) is a key enzyme system that catalyzes the conversion of L-arginine into nitric oxide (NO) and L-citrulline. It participates in vascular homeostasis, neural signaling, immune inflammation, and redox regulation. NOS research should not focus only on changes in NO levels; it should further distinguish NOS isoforms, enzymatic activity status, substrate and cofactor availability, NO bioavailability, and injury effects mediated by reactive nitrogen species.
Keywords: nitric oxide synthase; NOS; nitric oxide; NO; iNOS; eNOS; nNOS; L-arginine; L-citrulline; inflammatory response; oxidative stress; nitrite; nitrate; peroxynitrite; nitrative stress
1 Functional Positioning of Nitric Oxide Synthase
1.1 NOS-Catalyzed Reaction
(1) Reaction substrates and products
NOS uses L-arginine as the substrate and generates NO and L-citrulline in the presence of oxygen and reducing power. This reaction requires NADPH for electron donation and depends on structural components or cofactors such as heme, FAD, FMN, tetrahydrobiopterin (BH4), and calmodulin to maintain catalytic activity.
(2) Catalytic process
The NOS catalytic process includes substrate oxidation, electron transfer, and intermediate conversion, rather than a single simple oxidation reaction. Substrate concentration, cofactor status, dimer stability, calcium signaling, phosphorylation modification, and the redox environment can all affect NO production efficiency.
(3) NO signaling characteristics
NO is a small signaling molecule with a short half-life and strong diffusion capacity. It can activate soluble guanylate cyclase (sGC) and promote cGMP production. It can also participate in protein S-nitrosylation, metal-center regulation, and free-radical reactions.
1.2 Major NOS Isoforms
(1) nNOS/NOS1
nNOS is mainly distributed in the nervous system, skeletal muscle, and some epithelial tissues. It participates in neurotransmitter release, synaptic plasticity, neurovascular coupling, and smooth muscle regulation. Its activity is usually closely related to Ca²⁺/calmodulin signaling.
(2) iNOS/NOS2
iNOS is the inducible inflammatory NOS isoform and can be markedly expressed under stimulation by lipopolysaccharide, TNF-α, IL-1β, IFN-γ, and other inflammatory signals. Once expressed, iNOS can usually produce relatively high levels of NO continuously, making it a key isoform in studies of inflammatory responses, macrophage activation, and immune defense.
(3) eNOS/NOS3
eNOS is mainly present in vascular endothelial cells and participates in vasodilation, inhibition of platelet aggregation, endothelial barrier homeostasis, and blood-flow regulation. Its function is jointly regulated by shear stress, Ca²⁺ signaling, Akt-mediated phosphorylation, BH4 availability, and oxidative stress status.
Table 1 Major NOS Isoforms and Research Positioning
NOS Isoform | Common Name | Major Distribution / Scenario | NO Production Characteristics | Research Focus |
NOS1 | nNOS | Nervous system, skeletal muscle, some epithelial tissues | Strong local regulation, often associated with Ca²⁺ signaling | Neural signaling, synaptic function, neural injury |
NOS2 | iNOS | Macrophages, inflammatory cells, stimulated tissues | Can continuously produce high NO levels after induced expression | Inflammatory response, immune defense, nitrative stress |
NOS3 | eNOS | Vascular endothelial cells | Maintains low-level NO release under physiological conditions | Vasodilation, endothelial protection, cardiovascular function |
2 Regulatory Mechanisms of NOS-Mediated NO Production
2.1 Substrate and Cofactor Regulation
(1) L-arginine availability
L-arginine is the direct substrate for NOS-mediated NO production. When substrate supply is insufficient, NO production is limited, and the risk of abnormal NOS electron transfer may increase. Intracellular L-arginine levels are jointly influenced by transporters, arginase activity, protein catabolism, and the local microenvironment.
(2) BH4 status
BH4 is a key cofactor for maintaining coupled NOS catalysis and dimer stability. When BH4 is insufficient or oxidized to BH2, NOS may become uncoupled. Electrons are then not efficiently used for NO production but instead diverted to oxygen to generate superoxide anions, resulting in decreased NO and increased ROS simultaneously.
(3) NADPH and flavin cofactors
The NOS reductase domain relies on NADPH, FAD, and FMN for electron transfer. Insufficient NADPH supply or impaired electron transfer limits NO production and may change the direction of NOS-mediated redox reactions.
2.2 Enzyme Structure and Activity Status
(1) Dimer stability
Functional NOS usually exerts catalytic activity as a dimer. Dimer instability reduces NO production efficiency and increases the risk of uncoupling. BH4, heme binding, substrate availability, and oxidative stress all affect the dimeric structure.
(2) Calmodulin dependence
nNOS and eNOS are usually highly dependent on Ca²⁺/calmodulin regulation. iNOS binds calmodulin relatively stably; therefore, after induced expression, it can continuously produce NO under a broader range of Ca²⁺ conditions.
(3) Phosphorylation modification
eNOS is especially strongly regulated by phosphorylation. Phosphorylation at specific sites mediated by kinases such as Akt can enhance eNOS activity, whereas phosphorylation at inhibitory sites may reduce NO production. Inflammation, shear stress, insulin signaling, and oxidative stress can all affect eNOS phosphorylation status.
2.3 Competitive Metabolism and Endogenous Inhibition
(1) Arginase competition
Arginase competes with NOS for the substrate L-arginine and converts it into ornithine and urea. Increased arginase activity reduces substrate availability for NOS, thereby weakening NO production and potentially contributing to endothelial dysfunction and inflammatory microenvironment remodeling.
(2) ADMA inhibition
Asymmetric dimethylarginine (ADMA) is an endogenous competitive NOS inhibitor. Elevated ADMA is often associated with decreased NO production, abnormal endothelial function, and increased cardiovascular metabolic risk.
(3) Oxygen and mitochondrial status
The NOS reaction requires oxygen. Hypoxia, limited mitochondrial respiration, increased ROS, and changes in cellular reducing power can all affect NO production, NO consumption, and the duration of downstream NO signaling.
3 Role of NOS in Inflammatory Regulation
3.1 iNOS and Inflammatory NO Production
(1) Induced expression
Macrophages, monocytes, endothelial cells, epithelial cells, and smooth muscle cells can upregulate iNOS under inflammatory stimulation. Transcriptional regulatory pathways such as NF-κB, STAT1, and IRF often participate in iNOS expression induction.
(2) High-output NO release
The NO-producing capacity of iNOS is usually higher than the basal release levels of eNOS and nNOS. High levels of NO can participate in pathogen clearance, inflammatory factor regulation, and changes in immune cell function. However, sustained excessive production may cause tissue injury.
(3) Dual effects in inflammation
NO has concentration-dependent and context-dependent effects in inflammation. Moderate NO contributes to antibacterial, antiviral, and immunoregulatory functions; excessive NO readily reacts with ROS to generate reactive nitrogen species, promoting protein nitration, lipid peroxidation, and cellular injury.
3.2 NO and Immune Cell Function
(1) Macrophage activation
iNOS is often used as an important marker of classical inflammatory macrophage activation. Increased iNOS is usually accompanied by enhanced TNF-α, IL-6, IL-1β, and other inflammatory factors. However, iNOS expression levels can differ greatly depending on species, tissue source, and stimulation conditions.
(2) Pathogen clearance
NO and its derived reactive nitrogen species can inhibit microbial respiratory chains, disrupt metalloenzyme activity, damage DNA, and affect pathogen replication. They are important components of innate immune defense.
(3) Immunosuppression and tissue injury
In chronic inflammation, tumor microenvironments, and persistent infection, NO may suppress T-cell function, affect antigen presentation, or promote tissue structural damage. Therefore, increased iNOS cannot be simply interpreted as protective or damaging; it must be judged together with disease stage, cell type, and oxidative stress status.
3.3 Inflammatory Signaling Networks
(1) NF-κB pathway
LPS, TNF-α, and other stimuli can activate NF-κB and promote iNOS expression. iNOS is often used as an important readout for inflammatory activation and anti-inflammatory intervention evaluation.
(2) JAK/STAT pathway
IFN-γ can enhance iNOS transcription through the JAK/STAT pathway and plays an important role in macrophage inflammatory activation and pathogen defense responses.
(3) COX-2 and prostaglandin pathways
iNOS and COX-2 are often upregulated together in inflammatory models. NO, prostaglandins, and inflammatory factors show cross-regulation and can affect vascular permeability, pain, fever, and inflammatory cell recruitment.
Table 2 Common Observation Indicators for NOS in Inflammation Research
Observation Level | Representative Indicators | Main Significance | Interpretation Focus |
Enzyme expression | iNOS/NOS2 protein or mRNA | Capacity for inflammation-induced NO production | Should be interpreted with NO metabolites and cell type |
NO metabolites | Nitrite, nitrate | Reflect levels of stable NO metabolites | Affected by culture medium, serum, and reducing environment |
Inflammatory factors | TNF-α, IL-1β, IL-6 | Reflect degree of inflammatory activation | More reliable when analyzed together with iNOS |
Nitrative injury | 3-nitrotyrosine, nitrated proteins | Reflect reactive nitrogen species-related injury | Often indicates enhanced interaction between NO and ROS |
Cell phenotype | M1/M2-related markers | Determines immune cell functional status | Polarization should not be defined using iNOS alone |
4 Role of NOS in Oxidative Stress Research
4.1 Interaction Between NO and ROS
(1) Reaction between NO and superoxide anion
NO can rapidly react with superoxide anions to form peroxynitrite. This process reduces NO bioavailability while generating reactive nitrogen species with strong oxidative and nitrative capacity.
(2) Effects of peroxynitrite
Peroxynitrite can oxidize lipids, damage DNA, inhibit mitochondrial proteins, promote tyrosine nitration, and alter enzyme activity. 3-nitrotyrosine is often used as an indirect indicator of peroxynitrite-associated protein nitration.
(3) Reduced NO effectiveness
Under oxidative stress, even if NOS expression increases, effective NO signaling may decrease. Major causes include rapid NO consumption by ROS, eNOS uncoupling, BH4 oxidation, and increased ADMA.
4.2 NOS Uncoupling
(1) Basic mechanism
NOS uncoupling refers to the separation of NOS electron transfer from NO production. The enzyme no longer effectively generates NO and instead tends to generate superoxide anions. This status is one of the important mechanisms of endothelial dysfunction and inflammatory oxidative injury.
(2) Inducing factors
BH4 deficiency or oxidation, insufficient L-arginine, increased ADMA, abnormal heme structure, and enhanced oxidative stress can all induce or aggravate NOS uncoupling.
(3) Interpretation indicators
NOS uncoupling often manifests as decreased NO, increased ROS, reduced eNOS dimers, decreased BH4/BH2 ratio, and increased 3-nitrotyrosine. Measuring total NOS expression alone is insufficient to determine NOS functional status.
4.3 NO and Mitochondrial Function
(1) Respiratory-chain regulation
NO can interact with metal centers such as mitochondrial cytochrome c oxidase and affect electron transfer and oxygen consumption. Low-level NO regulation is usually reversible; under inflammation and oxidative stress, excessive NO/RNS may cause mitochondrial inhibition.
(2) Changes in energy metabolism
Excessive NO and reactive nitrogen species can inhibit mitochondrial enzyme activity, reduce ATP generation, and promote a cellular shift toward glycolytic metabolism. In inflammatory macrophages, NO signaling and metabolic reprogramming often occur simultaneously.
(3) Association with cellular injury
Excessive NO/RNS can induce DNA damage, PARP activation, mitochondrial membrane potential loss, and cell death. The final effect depends on NO concentration, duration, ROS background, and cell type.
Table 3 Interpretation of NOS-Related Oxidative and Nitrative Stress
Change Pattern | Possible Mechanism | Representative Indicators | Interpretation Direction |
NO increases, iNOS increases | Enhanced inflammation-induced NO production | iNOS, NO₂⁻/NO₃⁻ | Increased inflammatory activation or immune response |
NO decreases, ROS increases | NOS uncoupling or NO consumption by ROS | DHE, DCFH-DA, BH4/BH2 | Increased oxidative stress and decreased NO effectiveness |
3-nitrotyrosine increases | Peroxynitrite-associated protein nitration | 3-NT, nitrated proteins | Enhanced interaction between NO and superoxide anion |
eNOS expression remains normal but function decreases | Abnormal phosphorylation or uncoupling | p-eNOS, eNOS dimer | Decreased endothelial NO production capacity |
ATP decreases and mitochondria are damaged | RNS inhibits respiratory chain or induces injury | ATP, membrane potential, OCR | NO/RNS-related mitochondrial dysfunction |
5 Detection Strategies for NOS/NO Research
5.1 Direct and Indirect NO Detection
(1) Direct NO detection
NO has a short half-life and high reactivity, making direct detection difficult. NO electrodes, chemiluminescence, and EPR spin trapping can be used for dynamic NO analysis, but they require demanding instrumentation and sample handling conditions.
(2) Nitrite/nitrate detection
NO can be converted into nitrite and nitrate in aqueous and biological systems. The Griess method is commonly used to detect nitrite. If total NO metabolites need to be detected, nitrate is usually first reduced to nitrite before measurement.
(3) Fluorescent probe detection
DAF-type NO fluorescent probes can be used to observe intracellular NO-related signals. However, probe signals are affected by redox environment, cellular uptake, esterase activity, and other reactive nitrogen/oxygen species. They are more suitable for relative comparison and should not be used alone for absolute quantification.
5.2 NOS Expression and Enzyme Activity Detection
(1) mRNA and protein expression
qPCR, Western blot, ELISA, immunofluorescence, and immunohistochemistry can be used to detect NOS isoform expression. iNOS is suitable for inflammatory model evaluation, eNOS and p-eNOS for endothelial function research, and nNOS for neural model analysis.
(2) NOS enzyme activity detection
NOS activity detection is closer to functional status than expression detection alone. Enzyme activity assays can be based on conversion of L-arginine to L-citrulline, generation of NO metabolites, or coupled reaction systems.
(3) Isoform distinction
Different NOS isoforms have different sources and regulatory mechanisms. Experimental design should clarify whether the research target is iNOS-mediated inflammatory NO production or eNOS-mediated vascular protective NO release, and avoid directly attributing total NO changes to a single isoform.
5.3 Combined Oxidative Stress Detection
(1) ROS detection
NOS uncoupling and NO consumption are both related to ROS levels. DCFH-DA, DHE, MitoSOX, and other probes can help assess the oxidative stress background, but different probes differ in specificity for ROS species and subcellular localization.
(2) Nitrative injury detection
3-nitrotyrosine, protein S-nitrosylation, and nitrated protein levels can be used to determine the involvement of NO-derived reactive nitrogen species. These indicators are closer to the injury outcomes after NO interacts with oxidative stress.
(3) Antioxidant system detection
SOD, CAT, GSH, GSH-Px, Nrf2 pathway, MDA, and 4-HNE can be combined with NOS/NO detection to determine whether NO changes are accompanied by increased overall oxidative injury.
6 Application Scenarios
6.1 Inflammatory Model Research
In LPS-, cytokine-, or pathogen-related stimulation models, iNOS and NO metabolites are often used to evaluate the degree of inflammatory activation. If iNOS, NO₂⁻/NO₃⁻, and inflammatory factors decrease simultaneously after anti-inflammatory intervention, this usually suggests inhibition of inflammatory NO production.
6.2 Endothelial Function Research
eNOS is the core enzyme for endothelial NO production. Endothelial function studies should simultaneously focus on total eNOS protein, p-eNOS, NO production, ROS levels, and vasodilatory function. If eNOS expression remains unchanged but NO decreases, eNOS uncoupling or NO consumption by ROS should be considered first.
6.3 Neural Injury and Neuroinflammation Research
Both nNOS and iNOS may participate in NO changes in the nervous system. nNOS is more associated with neural signaling and local regulation, whereas iNOS is more often associated with neuroinflammation, microglial activation, and chronic injury. In neural models, the physiological signaling regulation of NO should be distinguished from RNS-mediated cellular injury.
6.4 Tumor Microenvironment Research
NO has concentration-dependent and stage-dependent effects in tumors. Low levels of NO may promote angiogenesis and tumor adaptation, whereas high levels of NO/RNS may induce DNA damage, cell death, or immune regulation. iNOS expression should be interpreted together with tumor type, immune infiltration, and oxidative stress background.
6.5 Pharmacology and Antioxidant Evaluation
The NOS/NO pathway is often used to evaluate the effects of anti-inflammatory drugs, antioxidants, endothelial protective agents, natural products, and metabolic modulators. Experimental design should include NOS isoforms, NO metabolites, ROS/RNS indicators, cell viability, and inflammatory factors, rather than relying on a single NO readout.
7 Common Issues and Result Interpretation
7.1 Does Increased NO Always Indicate Injury?
Increased NO does not necessarily indicate injury. Physiological eNOS-derived NO usually has vascular protective and signaling regulatory effects. In inflammatory states, NO generated by sustained high iNOS expression is more likely to form reactive nitrogen species with ROS and cause tissue injury. The significance of increased NO depends on its source, concentration, duration, and oxidative stress background.
7.2 Does Increased iNOS Equal Enhanced NO Effectiveness?
Increased iNOS usually suggests enhanced NO production potential. However, if ROS increases simultaneously, NO may be rapidly consumed and converted into peroxynitrite, leading to decreased effective NO signaling and enhanced nitrative injury.
7.3 Does Normal eNOS Expression Mean Normal Endothelial Function?
eNOS function depends on phosphorylation status, dimer stability, BH4 availability, L-arginine availability, and oxidative stress level. Normal eNOS expression with decreased NO is a common phenomenon in endothelial dysfunction research.
7.4 Can the Griess Method Represent Total NO Level?
The Griess method mainly detects nitrite. If the nitrate proportion in the sample is high, measuring nitrite alone will underestimate total NO metabolites. When detecting total NO metabolites, a nitrate reduction step should be included, or a total NO detection system should be used.
7.5 Can NO Fluorescent Probes Be Used for Absolute Quantification?
Most NO fluorescent probes are more suitable for relative comparison and imaging observation, not for absolute quantification alone. Probe signals should be validated together with negative controls, NOS inhibitors, positive stimulation, and other NO detection methods.
Table 4 Common Issues and Control Directions in NOS/NO Research
Problem | Possible Cause | Impact on Results | Control Direction |
NO metabolites increase | iNOS induction, enhanced inflammation | Indicates increased NO production | Detect iNOS and inflammatory factors simultaneously |
NO decreases while eNOS remains unchanged | eNOS uncoupling, NO consumption by ROS | Underestimates NOS functional abnormality | Detect ROS, BH4/BH2, and p-eNOS |
Griess signal is low | Nitrate fraction is not detected | Underestimates total NO metabolites | Add a nitrate reduction step |
Fluorescent probe background is high | Autofluorescence, redox interference | False positivity or poor reproducibility | Include probe blank and inhibitor controls |
iNOS increases with cell death | Excessive NO/RNS or inflammatory toxicity | Results are affected by cell viability | Combine with cell viability and cytotoxicity assays |
3-NT increases | Enhanced peroxynitrite formation | Indicates nitrative stress | Analyze together with NO, ROS, and antioxidant indicators |
8 Reagents and Detection Systems Related to NOS/NO Research
Table 5 Detection, Intervention, and Validation Products Related to NOS/NO Research
Product Category | Cat. No. | Product Name | Grade / Specification | Role in the System | Applicable Direction |
NO fluorescence detection | DAF-2 | ≥95%(HPLC) | Reacts with NO-related reactive species to form a fluorescent signal for NO observation | Intracellular NO imaging, NO production trend analysis, NOS inhibitor validation experiments | |
NO sample processing | Nitric oxide (NO) extraction reagent | BioReagent | Used for sample processing or extraction before NO detection | Pretreatment of tissue and cell samples before NO detection | |
NO detection lysis buffer | Cell and Tissue Lysis Buffer for Nitric Oxide Assay |
| Provides a compatible lysis system for NO detection | NO content detection in cell and tissue samples; pretreatment for Griess systems or NO assay kits | |
iNOS inhibitor | L-NIL | Moligand™, ≥99% | Inhibits iNOS-mediated inflammatory NO production | Inflammatory models, macrophage NO production, iNOS-dependence validation | |
nNOS inhibitor | NOS1-IN-1 | Moligand™, ≥98% | Inhibitor targeting NOS1/nNOS-related pathways | nNOS functional research, validation of nNOS-dependent NO signaling | |
NO donor | PAPA NONOate | ≥97% | Releases NO to establish an exogenous NO treatment system | NO positive control, NO signaling simulation, NO dose-response research | |
NO donor | DETA-NONOate | ≥95% | Sustained NO release, suitable for longer-term NO exposure models | Chronic NO treatment, inflammation/oxidative stress models, NO donor control | |
NO donor / anti-inflammatory small molecule | NCX 466 | ≥98%(HPLC) | Has both NO-donor and COX-related regulatory characteristics | NO-inflammation pathway crosstalk research, COX/NOS interaction analysis | |
NO-related small molecule | Quinoxaline N-oxide | ≥98% | NO-related nitrogen oxide research material | NO-related chemical models, oxidative/nitrative stress methodology research | |
NOS regulatory factor detection | Human Nitric Oxide Synthase Trafficker (NOSTRIN) ELISA Kit | BioReagent | Detects NOSTRIN level and helps evaluate eNOS localization and regulatory status | Endothelial NO pathway, eNOS membrane localization regulation, vascular function research | |
eNOS detection | Human Nitric Oxide Synthase 3, Endothelial (NOS3) ELISA Kit | BioReagent | Detects human NOS3/eNOS level | Endothelial function, vasodilation, eNOS-related NO production research | |
eNOS detection | Mouse Nitric Oxide Synthase 3, Endothelial (eNOS) ELISA Kit | BioReagent | Detects mouse eNOS level | Mouse vascular endothelial function, oxidative stress, and cardiovascular models | |
nNOS detection | Human Nitric Oxide Synthase 1, Neuronal (NOS1) ELISA Kit | BioReagent | Detects human NOS1/nNOS level | Neural NO signaling, neuroinflammation, neural injury models | |
iNOS detection | Rat Nitric Oxide Synthase 2, Inducible (INOS) ELISA Kit | BioReagent | Detects rat iNOS level | Rat inflammatory models, tissue injury, and NO production evaluation | |
iNOS recombinant protein | Recombinant Mouse NOS2 Protein | ≥90%(SDS-PAGE) | Provides mouse NOS2/iNOS recombinant protein | iNOS antibody validation, standard/positive control, method establishment | |
iNOS recombinant protein | Recombinant Human iNOS Protein | Carrier Free,Azide Free,His Tag,≥90%(SDS-PAGE) | Provides human iNOS recombinant protein | iNOS detection method validation, binding experiments, positive control | |
iNOS antibody | iNOS Mouse mAb | Carrier Free, ExactAb™, Azide Free, Validated, High Performance, See COA | Detects iNOS protein expression | Western blot, immunofluorescence, immunohistochemistry, inflammatory model validation | |
iNOS antibody | iNOS Mouse mAb | Animal Free,Carrier Free,ExactAb™,Azide Free,Validated,High Performance,PBS Only,≥95%(SDS-PAGE),1.0 mg/mL | High-purity iNOS monoclonal antibody | iNOS protein detection, inflammatory pathway analysis, antibody application validation | |
NOS1 gene silencing | NOS1 Human Pre-designed siRNA Set A |
| Targets human NOS1 transcript and reduces nNOS expression | nNOS functional validation, neural NO signaling research | |
Nos1 gene silencing | Nos1 Mouse Pre-designed siRNA Set A |
| Targets mouse Nos1 transcript | nNOS functional research in mouse-derived cells | |
Nos1 gene silencing | Nos1 Rat Pre-designed siRNA Set A |
| Targets rat Nos1 transcript | nNOS pathway research in rat-derived cells | |
NOS1 regulatory gene silencing | NOS1AP Human Pre-designed siRNA Set A |
| Targets NOS1AP and supports research on nNOS-related regulatory networks | nNOS localization, signaling complexes, and neural NO pathway research | |
NOS2 gene silencing | NOS2 Human Pre-designed siRNA Set A |
| Targets human NOS2 transcript and reduces iNOS expression | Inflammatory NO production, iNOS-dependence validation | |
Nos2 gene silencing | Nos2 Mouse Pre-designed siRNA Set A |
| Targets mouse Nos2 transcript | iNOS functional research in mouse macrophages and inflammatory cells | |
Nos2 gene silencing | NOS2 Rat Pre-designed siRNA Set A |
| Targets rat Nos2 transcript | iNOS pathway research in rat-derived inflammatory models | |
NOS3 gene silencing | NOS3 Human Pre-designed siRNA Set A |
| Targets human NOS3 transcript and reduces eNOS expression | Endothelial NO production, eNOS-dependence validation | |
Nos3 gene silencing | Nos3 Mouse Pre-designed siRNA Set A |
| Targets mouse Nos3 transcript | Mouse endothelial cells, cardiovascular and oxidative stress models | |
Nos3 gene silencing | Nos3 Rat Pre-designed siRNA Set A |
| Targets rat Nos3 transcript | Endothelial function and NO pathway research in rat-derived systems | |
NOS1 negative / validation material | pLenti-NOS1-sgRNA |
| Protein lysate with NOS1 knockout background | NOS1 antibody specificity validation, Western blot negative control | |
NOS1 negative / validation material | pLenti-NOS1-sgRNA |
| RNA lysate with NOS1 knockout background | NOS1 qPCR validation, transcription-level negative control | |
NOS2 negative / validation material | pLenti-NOS2-sgRNA |
| Protein lysate with NOS2 knockout background | iNOS antibody specificity validation, Western blot negative control | |
NOS2 negative / validation material | pLenti-NOS2-sgRNA |
| RNA lysate with NOS2 knockout background | NOS2 qPCR validation, transcription-level negative control | |
NOS3 negative / validation material | pLenti-NOS3-sgRNA |
| Protein lysate with NOS3 knockout background | eNOS antibody specificity validation, Western blot negative control | |
NOS3 negative / validation material | pLenti-NOS3-sgRNA |
| RNA lysate with NOS3 knockout background | NOS3 qPCR validation, transcription-level negative control |
NOS/NO research should distinguish NO production capacity, effective NO bioavailability, and NO-derived injury effects. In inflammation, endothelial function, and oxidative stress models, NOS isoform expression, NOS enzymatic activity, NO metabolites, ROS/RNS indicators, and cellular functional readouts should be analyzed together to accurately determine the role of the NO pathway in a specific experimental system.